Routes and molecular mechanisms of central nervous system involvement in acute myeloid leukemia (Review)
- Authors:
- Liucui Chen
- Piaorong Zeng
- Huifang Tang
- Gang Chen
- Juan Xie
- Xiaoyan Yang
- Xiaoyong Lei
-
Affiliations: School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Hematology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China, Hunan Provincial Key Laboratory of Multi‑omics and Artificial Intelligence of Cardiovascular Diseases, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Neurology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P.R. China - Published online on: August 28, 2024 https://doi.org/10.3892/or.2024.8805
- Article Number: 146
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Korn C and Méndez-Ferrer S: Myeloid malignancies and the microenvironment. Blood. 129:811–822. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Munker R, Labopin M, Esteve J, Schmid C, Mohty M and Nagler A: Mixed phenotype acute leukemia: Outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica. 102:2134–2140. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, et al: Transient leukemia of Down syndrome. Crit Rev Clin Lab Sci. 56:247–259. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dima D, Oprita L, Rosu AM, Trifa A, Selicean C, Moisoiu V, Frinc I, Zdrenghea M and Tomuleasa C: Adult acute megakaryoblastic leukemia: Rare association with cytopenias of undetermined significance and p210 and p190 BCR-ABL transcripts. Onco Targets Ther. 10:5047–5051. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gafencu GA, Tomuleasa CI and Ghiaur G: PARP inhibitors in acute myeloid leukaemia therapy: How a synthetic lethality approach can be a valid therapeutic alternative. Med Hypotheses. 104:30–34. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S and Gamis AS: Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 64:102017. View Article : Google Scholar : PubMed/NCBI | |
|
Constantinescu C, Bodolea C, Pasca S, Teodorescu P, Dima D, Rus I, Tat T, Achimas-Cadariu P, Tanase A, Tomuleasa C and Einsele H: Clinical Approach to the Patient in Critical State Following Immunotherapy and/or Stem Cell Transplantation: Guideline for the On-Call Physician. J Clin Med. 8:8842019. View Article : Google Scholar : PubMed/NCBI | |
|
Goulart H, Sastow D, Moshier E, Martin L, Mascarenhas J and Tremblay D: Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement. Leuk Res. 137:1074522024. View Article : Google Scholar : PubMed/NCBI | |
|
Alakel N, Stölzel F, Mohr B, Kramer M, Oelschlägel U, Röllig C, Bornhäuser M, Ehninger G and Schaich M: Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Cancer Manag Res. 9:97–102. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng CL, Li CC, Hou HA, Fang WQ, Chang CH, Lin CT, Tang JL, Chou WC, Chen CY, Yao M, et al: Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer. 15:3442015. View Article : Google Scholar : PubMed/NCBI | |
|
Felix A, Leblanc T, Petit A, Nelkem B, Bertrand Y, Gandemer V, Sirvent A, Paillard C, Schmitt C, Rohrlich PS, et al: Acute Myeloid Leukemia With Central Nervous System Involvement in Children: Experience From the French Protocol Analysis ELAM02. J Pediatr Hematol Oncol. 40:43–47. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ganzel C, Lee JW, Fernandez HF, Paietta EM, Luger SM, Lazarus HM, Cripe LD, Douer D, Wiernik PH, Rowe JM, et al: CNS involvement in AML at diagnosis is rare and does not affect response or survival: Data from 11 ECOG-ACRIN trials. Blood Adv. 5:4560–4568. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC, Maiti A, Ravandi F, Cortes J, Abi Aad S, Garcia-Manero G, et al: Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. Am J Hematol. 92:924–928. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Del Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A, Consalvo MI, Paterno G, Sarlo C, De Bellis E, et al: Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. Semin Hematol. 55:209–214. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bojsen-Møller M and Nielsen JL: CNS involvement in leukaemia. An autopsy study of 100 consecutive patients. Acta Pathol Microbiol Immunol Scand A. 91:209–216. 1983.PubMed/NCBI | |
|
Paul S and Short NJ: Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management. Curr Oncol Rep. 24:427–436. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Virijevic M, Kraguljac-Kurtovic N, Mitrovic M, Jakovic L, Bukumuric Z, Pantic N, Sabljic N, Pravdic Z, Cvetkovic M, Knezevic V, et al: Incidence, risk factors, and outcome of asymptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Hematol Oncol. 42:e32532024. View Article : Google Scholar : PubMed/NCBI | |
|
Bar M, Tong W, Othus M, Loeb KR and Estey EH: Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 21:546–551. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Bento LC, Correia RP, Alexandre AM, Nosawa ST, Pedro EC, Vaz ADC, Schimidell D, Fernandes GBP, Duarte CAS, Barroso RS and Bacal NS: Detection of Central Nervous System Infiltration by Myeloid and Lymphoid Hematologic Neoplasms Using Flow Cytometry Analysis: Diagnostic Accuracy Study. Front Med (Lausanne). 5:702018. View Article : Google Scholar : PubMed/NCBI | |
|
Ranta S, Palomäki M, Levinsen M, Taskinen M, Abrahamsson J, Hasle H, Jahnukainen K, Heyman M and Harila-Saari A; Nordic Society of Pediatric Haematology Oncology (NOPHO), : Presenting features and imaging in childhood acute myeloid leukemia with central nervous system involvement. Pediatr Blood Cancer. 64:2017. View Article : Google Scholar | |
|
Reid JH, Perissinotti AJ, Benitez L, Bixby DL, Burke P, Pettit K and Marini BL: Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. Leuk Lymphoma. 61:862–868. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Berg S and Nand S: Neurological Complications of the Leukemias Across the Ages. Curr Neurol Neurosci Rep. 17:132017. View Article : Google Scholar : PubMed/NCBI | |
|
Chamberlain MC, Glantz M, Groves MD and Wilson WH: Diagnostic tools for neoplastic meningitis: Detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol. 36 (4 Suppl 2):S35–S45. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Thakkar JP, Kumthekar P, Dixit KS, Stupp R and Lukas RV: Leptomeningeal metastasis from solid tumors. J Neurol Sci. 411:1167062020. View Article : Google Scholar : PubMed/NCBI | |
|
Duzova A and Bakkaloglu A: Central nervous system involvement in pediatric rheumatic diseases: Current concepts in treatment. Curr Pharm Des. 14:1295–1301. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ebadi M, Morse M, Gooley T, Ermoian R, Halasz LM, Lo SS, Yang JT, Blau MH, Percival ME, Cassaday RD, et al: Craniospinal irradiation for CNS leukemia: Rates of response and durability of CNS control. J Neurooncol. 166:351–357. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Siegal T, Benouaich-Amiel A and Bairey O: Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities. Blood Rev. 53:1009102022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Q, Zhu XL, Zhao X, Liu X, Fu HX, Zhang YY, Chen YH, Mo XD, Han W, Chen H, et al: Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Ann Hematol. 100:505–516. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Su A, Liu X, Tong Z, Jiang Q and Yu J: Effects of D-CAG chemotherapy regimen on cognitive function in patients with acute myeloid leukaemia: A resting-state functional magnetic resonance imaging study. Eur J Neurosci. 59:119–131. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Zhong JF and Zhang X: Revealing the molecular mechanism of central nervous system leukemia with single-cell technology. Crit Rev Oncol Hematol. 153:1030462020. View Article : Google Scholar : PubMed/NCBI | |
|
Si M, Jiao X, Li Y, Chen H, He P and Jiang F: The role of cytokines and chemokines in the microenvironment of the blood-brain barrier in leukemia central nervous system metastasis. Cancer Manag Res. 10:305–313. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nourshargh S and Alon R: Leukocyte migration into inflamed tissues. Immunity. 41:694–707. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ley K, Laudanna C, Cybulsky MI and Nourshargh S: Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol. 7:678–689. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Maloney MA, Forsyth RP and Patt HM: Bone marrow blood flow after marrow removal or nutrient vessel ligation. Proc Soc Exp Biol Med. 135:871–873. 1970. View Article : Google Scholar : PubMed/NCBI | |
|
Kusumbe AP, Ramasamy SK and Adams RH: Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. 507:323–328. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tavassoli M: The marrow-blood barrier. Br J Haematol. 41:297–302. 1979. View Article : Google Scholar : PubMed/NCBI | |
|
Petrides PE and Dittmann KH: How do normal and leukemic white blood cells egress from the bone marrow? Morphological facts and biochemical riddles. Blut. 61:3–13. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Wight TN: Cell biology of arterial proteoglycans. Arteriosclerosis. 9:1–20. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Owen M: Marrow stromal stem cells. J Cell Sci Suppl. 10:63–76. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Inoue S and Osmond DG: Basement membrane of mouse bone marrow sinusoids shows distinctive structure and proteoglycan composition: A high resolution ultrastructural study. Anat Rec. 264:294–304. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Bentley SA and Foidart JM: Some properties of marrow derived adherent cells in tissue culture. Blood. 56:1006–1012. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Leonardi GP, Manthos M, Orlic D and Lobue J: Morphometric analysis of bone marrow sinus cell elements after induction of monomyelocytic leukemia in BALB/c mice. Anat Rec. 224:331–335. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Kuto F, Nagaoka T, Watanabe Y, Hayashi M, Horasawa Y, Hirasawa Y and Tokuhiro H: Chronic myelocytic leukemia: Ultrastructural histopathology of bone marrow from patients in the chronic phase. Ultrastruct Pathol. 6:307–317. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaoka T, Kuto F, Watanabe Y, Fujino Y, Hirasawa Y and Tokuhiro H: Bone marrow sinus and cell egress in human leukaemia: a morphometric study of core biopsies using wide-field electron microscopy. Br J Haematol. 63:737–747. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Gordon MY: Extracellular matrix of the marrow microenvironment. Br J Haematol. 70:1–4. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, et al: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature. 382:833–835. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Möhle R, Bautz F, Rafii S, Moore MA, Brugger W and Kanz L: The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 91:4523–4530. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Möhle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W and Kanz L: Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol. 110:563–572. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Newman PJ, Berndt MC, Gorski J, White GC II, Lyman S, Paddock C and Muller WA: PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. 247:1219–1222. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Muller WA, Weigl SA, Deng X and Phillips DM: PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med. 178:449–460. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, Walseth TF and Lee HC: Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 262:1056–1059. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Nishina H, Inageda K, Takahashi K, Hoshino S, Ikeda K and Katada T: Cell surface antigen CD38 identified as ecto-enzyme of NAD glycohydrolase has hyaluronate-binding activity. Biochem Biophys Res Commun. 203:1318–1323. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Gallay N, Anani L, Lopez A, Colombat P, Binet C, Domenech J, Weksler BB, Malavasi F and Herault O: The role of platelet/endothelial cell adhesion molecule 1 (CD31) and CD38 antigens in marrow microenvironmental retention of acute myelogenous leukemia cells. Cancer Res. 67:8624–8632. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dercksen MW, Gerritsen WR, Rodenhuis S, Dirkson MK, Slaper-Cortenbach IC, Schaasberg WP, Pinedo HM, von dem Borne AE and van der Schoot CE: Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood. 85:3313–3319. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Torensma R, Raymakers RA, van Kooyk Y and Figdor CG: Induction of LFA-1 on pluripotent CD34+ bone marrow cells does not affect lineage commitment. Blood. 87:4120–4128. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Möhle R, Moore MA, Nachman RL and Rafii S: Transendothelial migration of CD34+ and mature hematopoietic cells: An in vitro study using a human bone marrow endothelial cell line. Blood. 89:72–80. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Yong KL, Watts M, Shaun Thomas N, Sullivan A, Ings S and Linch DC: Transmigration of CD34+ cells across specialized and nonspecialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31). Blood. 91:1196–1205. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Zhang X, Fan X, Li D and Qiao Z: Effect of ICAM-1 and LFA-1 in hyperleukocytic acute myeloid leukaemia. Clin Lab Haematol. 28:177–182. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Liu T, Liu X, Xiang J, Zou P, Zhou J, Chen Y, Yu D and Li C: Study on the relationship between the expression of adhesion molecules and the invasiveness of acute myeloid leukemia cells. Zhonghua Xue Ye Xue Za Zhi. 18:29–31. 1997.(In Chinese). PubMed/NCBI | |
|
Cook-Mills JM, Marchese ME and Abdala-Valencia H: Vascular cell adhesion molecule-1 expression and signaling during disease: Regulation by reactive oxygen species and antioxidants. Antioxid Redox Signal. 15:1607–1638. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Meigs JB, Hu FB, Rifai N and Manson JE: Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 291:1978–1986. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Dessein PH, Joffe BI and Singh S: Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther. 7:R634–R643. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe T, Dave B, Heimann DG, Jackson JD, Kessinger A and Talmadge JE: Cell adhesion molecule expression on CD34+ cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation. Exp Hematol. 26:10–18. 1998.PubMed/NCBI | |
|
Jing M, Chen X, Qiu H, He W, Zhou Y, Li D, Wang D, Jiao Y and Liu A: Insights into the immunomodulatory regulation of matrix metalloproteinase at the maternal-fetal interface during early pregnancy and pregnancy-related diseases. Front Immunol. 13:10676612023. View Article : Google Scholar : PubMed/NCBI | |
|
Pirillo C, Birch F, Tissot FS, Anton SG, Haltalli M, Tini V, Kong I, Piot C, Partridge B, Pospori C, et al: Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 6:3126–3141. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Song JH, Kim SH, Cho D, Lee IK, Kim HJ and Kim TS: Enhanced invasiveness of drug-resistant acute myeloid leukemia cells through increased expression of matrix metalloproteinase-2. Int J Cancer. 125:1074–1081. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ismair MG, Ries C, Lottspeich F, Zang C, Kolb HJ and Petrides PE: Autocrine regulation of matrix metalloproteinase-9 gene expression and secretion by tumor necrosis factor-alpha (TNF-alpha) in NB4 leukemic cells: Specific involvement of TNF receptor type 1. Leukemia. 12:1136–1143. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Janowska-Wieczorek A, Marquez LA, Matsuzaki A, Hashmi HR, Larratt LM, Boshkov LM, Turner AR, Zhang MC, Edwards DR and Kossakowska AE: Expression of matrix metalloproteinases (MMP-2 and −9) and tissue inhibitors of metalloproteinases (TIMP-1 and −2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol. 105:402–411. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tavor S, Petit I, Porozov S, Goichberg P, Avigdor A, Sagiv S, Nagler A, Naparstek E and Lapidot T: Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. Blood. 106:2120–2127. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Shechter R, London A and Schwartz M: Orchestrated leukocyte recruitment to immune-privileged sites: Absolute barriers versus educational gates. Nat Rev Immunol. 13:206–218. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Price RA: Histopathology of CNS leukemia and complications of therapy. Am J Pediatr Hematol Oncol. 1:21–30. 1979.PubMed/NCBI | |
|
Spadoni I, Fornasa G and Rescigno M: Organ-specific protection mediated by cooperation between vascular and epithelial barriers. Nat Rev Immunol. 17:761–773. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Deak D, Gorcea-Andronic N, Sas V, Teodorescu P, Constantinescu C, Iluta S, Pasca S, Hotea I, Turcas C, Moisoiu V, et al: A narrative review of central nervous system involvement in acute leukemias. Ann Transl Med. 9:682021. View Article : Google Scholar : PubMed/NCBI | |
|
Cugurra A, Mamuladze T, Rustenhoven J, Dykstra T, Beroshvili G, Greenberg ZJ, Baker W, Papadopoulos Z, Drieu A, Blackburn S, et al: Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science. 373:eabf78442021. View Article : Google Scholar : PubMed/NCBI | |
|
Azzarelli V and Roessmann U: Pathogenesis of central nervous system infiltration in acute leukemia. Arch Pathol Lab Med. 101:203–205. 1977.PubMed/NCBI | |
|
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, et al: Structural and functional features of central nervous system lymphatic vessels. Nature. 523:337–341. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H and Alitalo K: A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 212:991–999. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M and Kipnis J: Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest. 127:3210–3219. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, et al: A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 4:147ra1112012. View Article : Google Scholar : PubMed/NCBI | |
|
Guerrini MM, Okamoto K, Komatsu N, Sawa S, Danks L, Penninger JM, Nakashima T and Takayanagi H: Inhibition of the TNF Family Cytokine RANKL prevents autoimmune inflammation in the central nervous system. Immunity. 43:1174–1185. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Maeda A, Kobayashi Y, Saito T, Togitani K, Kawahigashi N, Tanosaki R, Takaue Y, Takenaka T, Iwata N and Tobinai K: Central nervous system relapse with multiple brain masses in an acute promyelocytic leukemia patient treated with all-trans retinoic acid. Rinsho Ketsueki. 40:1081–1086. 1999.(In Japanese). PubMed/NCBI | |
|
Raanani P, Shpilberg O and Ben-Bassat I: Extramedullary disease and targeted therapies for hematological malignancies-is the association real? Ann Oncol. 18:7–12. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Zhang D, Cui X, Dai Y, Wang C, Feng W, Lv X, Li Y, Wang L, Ru Y, et al: Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion. Oncogene. 41:2303–2314. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Chang H, Brandwein J, Yi QL, Chun K, Patterson B and Brien B: Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res. 28:1007–1011. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yang SW, Ma RJ, Yuan XL, Jiang L, Li YL, Dong XY, Wang Z, Zhang L, Shang BJ, Lei PC and Zhu ZM: Correlation analysis of central nervous system relapse and cell biological characteristics in acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 42:517–520. 2021.(In Chinese). PubMed/NCBI | |
|
Bergstrom CP, Dahiya S, Chen W, Zhang CC, Zhu H, Yan J, Madanat Y, Patel P, Vusirkala M, Ramakrishnan P, et al: The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement. Leuk Res. 100:1064802021. View Article : Google Scholar : PubMed/NCBI | |
|
Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, et al: LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 562:605–609. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Deng M, Huang F, Jin C, Sun S, Chen H, Liu X, He L, Sadek AH and Zhang CC: LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cells. Cell Mol Immunol. 17:272–282. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bonoiu A, Mahajan SD, Ye L, Kumar R, Ding H, Yong KT, Roy I, Aalinkeel R, Nair B, Reynolds JL, et al: MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 1282:142–55. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Stefanidakis M, Karjalainen K, Jaalouk DE, Gahmberg CG, O'Brien S, Pasqualini R, Arap W and Koivunen E: Role of leukemia cell invadosome in extramedullary infiltration. Blood. 114:3008–3017. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Röllig C and Ehninger G: How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 125:3246–3252. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Wang YY, Dai YJ, Zhang W, Zhang WN, Xiong SM, Gu ZH, Wang KK, Zeng R, Chen Z and Chen SJ: DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci USA. 111:2620–2625. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Zhang W, Yan XJ, Lin XQ, Li W, Mi JQ, Li JM, Zhu J, Chen Z and Chen SJ: DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1. J Hematol Oncol. 9:1062016. View Article : Google Scholar : PubMed/NCBI | |
|
Li ZJ, Chen ZX, Cen JN and He J: Overexpression of tissue inhibitor of metalloprotease-2 promotes proliferation and infiltration of human monocytic leukemia cells. Zhonghua Yi Xue Za Zhi. 86:2409–2412. 2006.(In Chinese). PubMed/NCBI | |
|
Yan XJ, Xu J, Gu ZH, Pan CM, Lu G, Shen Y, Shi JY, Zhu YM, Tang L, Zhang XW, et al: Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 43:309–315. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Landry B, Gül-Uludağ H, Plianwong S, Kucharski C, Zak Z, Parmar MB, Kutsch O, Jiang H, Brandwein J and Uludağ H: Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. J Control Release. 224:8–21. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, et al: A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 119:3917–3924. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Peled A and Tavor S: Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics. 3:34–39. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Meng J, Ge Y, Xing H, Wei H, Xu S, Liu J, Yan D, Wen T, Wang M, Fang X, et al: Synthetic CXCR4 antagonistic peptide assembling with nanoscaled micelles combat acute myeloid leukemia. Small. 16:e20018902020. View Article : Google Scholar : PubMed/NCBI | |
|
Yue S, An J, Zhang Y, Li J, Zhao C, Liu J, Liang L, Sun H, Xu Y and Zhong Z: Exogenous antigen upregulation empowers antibody targeted nanochemotherapy of leukemia. Adv Mater. 35:e22099842023. View Article : Google Scholar : PubMed/NCBI | |
|
Sayitoglu EC, Luca BA, Boss AP, Thomas BC, Freeborn RA, Uyeda MJ, Chen PP, Nakauchi Y, Waichler C, Lacayo N, et al: AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML. Leukemia. 38:1246–1255. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman E and Rafii S: The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood. 111:1951–1961. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
John S, Chen H, Deng M, Gui X, Wu G, Chen W, Li Z, Zhang N, An Z and Zhang CC: A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. Mol Ther. 26:2487–2495. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang H and Li H: Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: A systematic review and meta-analysis. BMC Cancer. 21:1492021. View Article : Google Scholar : PubMed/NCBI | |
|
Bharadwaj S, Sahoo AK and Yadava U: Editorial: Advances in the therapeutic targeting of human matrix metalloproteinases in health and disease. Front Mol Biosci. 10:11504742023. View Article : Google Scholar : PubMed/NCBI | |
|
Levin M, Udi Y, Solomonov I and Sagi I: Next generation matrix metalloproteinase inhibitors-Novel strategies bring new prospects. Biochim Biophys Acta Mol Cell Res. 1864((11 Pt A)): 1927–1939. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Winer A, Adams S and Mignatti P: Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. Mol Cancer Ther. 17:1147–1155. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Narla RK, Dong Y, Klis D and Uckun FM: Bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(I.V.) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity. Clin Cancer Res. 7:1094–1101. 2001.PubMed/NCBI | |
|
Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, Wong K, Pathuri S, Briand J, Steidel M, et al: Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2:1002–1017. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Bäumer N, Scheller A, Wittmann L, Faust A, Apel M, Nimmagadda SC, Geyer C, Grunert K, Kellmann N, Peipp M, et al: Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. J Hematol Oncol. 15:1712022. View Article : Google Scholar : PubMed/NCBI |
